{"analyses":[{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.02","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.35","paramType":"Cox Proportional Hazard","paramValue":"1.12","statisticalComment":"stratified log rank test was used, stratifying the randomization factors (ECOG PS 0-1 vs ECOG PS 2; GI vs Pancreatic NET).","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.4","upperLimit":"30.3","value":"12.6"},{"groupId":"OG001","lowerLimit":"9.6","upperLimit":"21.1","value":"10.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"OS is defined as the time from randomization to death from any cause. OS is censored at the date of last contact. Median OS is estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (Capecitabine, Temozolomide)"},{"description":"Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm B (Cisplatin, Carboplatin, Etoposide)"}],"paramType":"MEDIAN","populationDescription":"All eligible patients","reportingStatus":"POSTED","timeFrame":"assessed at baseline, then every 3 months within 2 years from randomization, and every 6 months if patient is 3-5 years from randomization, up to 5 years from randomization","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}